加味四君子汤治疗直肠癌术后患者的疗效分析
|
摘要
目的分析加味四君子汤联合化疗药对直肠癌术后患者的疗效。方法将我院收治的120例直肠癌术后患者随机分为两组,对照组给予FOLFOX-7化疗方案,治疗组给予FOLFOX-7+加味四君子汤,治疗4个疗程,评价两组的KPS评分、有效率和T细胞亚群的变化情况。结果治疗后,两组的KPS评分较治疗前均显著提高,且治疗组优于对照组(P<0.05);治疗组有效率86.7%显著高于对照组61.7%(P<0.05);治疗后,对照组的T细胞亚群无变化,治疗组的CD3+,CD4+和CD4+/CD8+较治疗前均升高,且显著优于同期对照组(P<0.05)。结论加味四君子汤联合FOLFOX-7化疗方案治疗直肠癌术后患者,可以明显提高患者生活质量,改善患者免疫功能状态。
Objective To analyze the efficacy of Jiawei Sijunzi Decoction combined with chemotherapy in patients with rectal cancer. Methods 120 patients with rectal cancer admitted to our hospital were randomLy divided into two groups. The control group was given FOLFOX-7 chemotherapy regimen, and the treatment group was given FOLFOX-7+ Jiawei Sijunzi decoction for 4 courses.KPS scores, effective rates, and changes in T cell subsets were evaluated in both groups. Results After treatment, the KPS scores of the two groups were significantly higher than those before treatment, and the treatment group was superior to the control group(P<0.05).The effective rate of treatment group was 86.7% significantly higher than that of the control group 61.7%(P<0.05); After treatment,there was no change in the T cell subsets in the control group. The CD3+, CD4+ and CD4+/CD8+ in the treatment group were higher than those in the control group, and were significantly better than the control group(P<0.05). Conclusions Jiawei Sijunzi Decoction combined with FOLFOX-7 chemotherapy for patients with postoperative rectal cancer can significantly improve the quality of life of patients and improve the immune function of patients.
Objective To analyze the efficacy of Jiawei Sijunzi Decoction combined with chemotherapy in patients with rectal cancer. Methods 120 patients with rectal cancer admitted to our hospital were randomLy divided into two groups. The control group was given FOLFOX-7 chemotherapy regimen, and the treatment group was given FOLFOX-7+ Jiawei Sijunzi decoction for 4 courses.KPS scores, effective rates, and changes in T cell subsets were evaluated in both groups. Results After treatment, the KPS scores of the two groups were significantly higher than those before treatment, and the treatment group was superior to the control group(P<0.05).The effective rate of treatment group was 86.7% significantly higher than that of the control group 61.7%(P<0.05); After treatment,there was no change in the T cell subsets in the control group. The CD3+, CD4+ and CD4+/CD8+ in the treatment group were higher than those in the control group, and were significantly better than the control group(P<0.05). Conclusions Jiawei Sijunzi Decoction combined with FOLFOX-7 chemotherapy for patients with postoperative rectal cancer can significantly improve the quality of life of patients and improve the immune function of patients.
引文
[1]王继恒,李世荣.我国结直肠癌筛查和早期诊断十年回顾(1994-2005)[J]胃肠病学,2006,11(4):245.
[2]宋春燕,王翠英,沈凤梅.四君子汤加减联合化疗治疗III期大肠癌29例的体会[J].贵阳中医学院学报,2012,34(1):57-58.
[3]崔钰珠,于慧会,崔巧研,等.四君子汤加减改善大肠癌患者生存质量研究进展[L].辽宁中医药大学学报,2017,2(2):74-76.
[4]杨新中.对中医肿瘤病因病机与治疗思考[J].中国医药学报,1999,14(6):57-60.
[5]岳顺.四君子汤对直肠癌术后免疫功能和生活质量的影响[J].南京中医药大学学报,2016,32(4):334-336.
[6]冯彦.人参药理作用及临床应用研究进展[J].中医临床研究,2013,5(5):122.
[7]沈国庆.白术化学成分及抗肿瘤有效部位研究[J]中医中药,2012,10(21):608.
[8]刁铁成.茯苓药理作用的初步研究[J].中医临床研究,2015,7(8):3-5.
[9]杨晓露,刘朵,卞卡,等.甘草总黄酮及其成分体外抗炎活性及其研究[J].中国中药杂志,2013,38(1):99-103.
[10]孙波,王志敏,沈静,等.健脾益气联合化疗治疗晚期大肠癌临床观察[J].辽宁中医杂志,2015,42(3):518-520.
[2]宋春燕,王翠英,沈凤梅.四君子汤加减联合化疗治疗III期大肠癌29例的体会[J].贵阳中医学院学报,2012,34(1):57-58.
[3]崔钰珠,于慧会,崔巧研,等.四君子汤加减改善大肠癌患者生存质量研究进展[L].辽宁中医药大学学报,2017,2(2):74-76.
[4]杨新中.对中医肿瘤病因病机与治疗思考[J].中国医药学报,1999,14(6):57-60.
[5]岳顺.四君子汤对直肠癌术后免疫功能和生活质量的影响[J].南京中医药大学学报,2016,32(4):334-336.
[6]冯彦.人参药理作用及临床应用研究进展[J].中医临床研究,2013,5(5):122.
[7]沈国庆.白术化学成分及抗肿瘤有效部位研究[J]中医中药,2012,10(21):608.
[8]刁铁成.茯苓药理作用的初步研究[J].中医临床研究,2015,7(8):3-5.
[9]杨晓露,刘朵,卞卡,等.甘草总黄酮及其成分体外抗炎活性及其研究[J].中国中药杂志,2013,38(1):99-103.
[10]孙波,王志敏,沈静,等.健脾益气联合化疗治疗晚期大肠癌临床观察[J].辽宁中医杂志,2015,42(3):518-520.